Oncolytics Biotech Inc T.ONC

Roche/Genentech in race for CAR-T therapy in solid tumors

[Noteable]

September 27, 2022 - "In the race to create a CAR-T therapy that can treat solid tumors, Genentech has decided it needs all the help it can get. The Roche unit has fronted $70 million to use Arsenal Biosciences’ armory of screening and T-cell engineering tools to find a truly successful target."

"The first generation of CAR-Ts scored successes against hematological malignancies, and Big Pharma already has its sights set on the next generation including "off-the-shelf" variations. Yet an approval to treat solid tumors has remained tantalizing out of reach, with Novartis and AstraZeneca among the big players that have outlined their solid tumor CAR-T ambitions..."

"Roche has been late to the CAR-T game, only joining the action last year with a $3 billion Adaptimmune Therapeutics deal for off-the-shelf T-cell therapies followed by a $110 million agreement with Poseida Therapeutics for a clutch of CAR-Ts last month."

https://www.fiercebiotech.com/biotech/genentech-pays-70m-access-arsenals-armoury-t-cell-tools-quest-solid-tumor-car-t

[Noteable]

December 06, 2022- Poseida Therapeutics, Inc.  early stage product P-BCMA-ALLO1 is an allogeneic CAR-T product candidate, partnered with Roche, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma in Phase 1 development. product. Early clinical (safety) results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1

[Noteable]

December 01, 2022 - Roche’s Genentech unit is walking away from a clutch of studies for its leading Alzheimer’s therapy gantenerumab weeks after the monoclonal antibody failed a pair of phase 3 studies. https://www.fiercebiotech.com/biotech/roche-thins-alzheimers-program-after-phase-3-failure-may-seek-external-partnerships This pull-back re-emphasizes Roche's decision to re-focus its

[westcoast1000]

Thanks, Notable for alerting us to Roche's involvement in CAR-T. That is another reason they should acquire ONCY.

[fox7mf]

I wasn't aware, until just now, that Coffey wasn't attending the presentation tomorrow & Dr Houra was handling it. With the buzz around tomorrow, the release of formerly embargoed data, there must be good reason he isn't in Boston. The man does like the spotlight. Perhaps negotiations are at the stage where either Parsons or Rigby or both requested his presence? GL for tomorrow all

[Noteable]

Houra is the lead investigator and this is her study. She knows the most about the findings. Not Coffey.

[Noteable]

Furthermore, Houra Loghmani's Goblet 1 pancreatic cancer study does not belong under this subject header.

[westcoast1000]

"Houra is the lead investigator and this is her study. She knows the most about the findings. Not Coffey." Exactly. It is a science meeting. The investigator gives the talk.

[Noteable]

Although recent clinical trials have shown greater success in CAR-T cell therapy than conventional treatments in some patients, there are currently three major limitations to CAR-T cell therapy: cell exhaustion, antigen recognition, and prediction of patient response. Together, they explain why CAR-T cell therapy has only been successful in hematological cancers and limited in the treatment

[Noteable]

And how many other big pharma companies are interested in ONCY's pelareorep in combination with their CAR-T therapies in solid tumors ? More than a few ...  Just sayn'...

[Noteable]

And here's one reason why ...CAR-T  therapy,  then there is immune checkpoint inhibitors in pancreatic cancer, then .... you finish the sentence...